Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Astellas Pharma’s 7.6% decline in half-year Japan sales is mainly attributed to a biennial drug price revision in April, especially a 25% re-pricing of its prostate cancer med Xtandi (enzalutamide), President Yoshihiko Hatanaka said on October 28. “The 25% price…
To read the full story
Related Article
- Astellas Sees Sales Drop, but Profits Grow on Lower Costs
October 31, 2016
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





